GlassScriptPhysician profile
Anwar Tandar
NPI 1154538148
$131,477.23
in general payments reported to CMS, 2019-2025
14 companies · $51K in 2025
The $51K reported for 2025 was more than what 97% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $13K · 2021: $2,400 · 2022: $21K · 2023: $12K · 2024: $9,303 · 2025: $51K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $50K · Travel and Lodging: $15K · Food and Beverage: $7,906.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $49,658.75 |
| Travel and Lodging | $15,131.20 |
| Food and Beverage | $7,905.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $49,851.90 | 2019-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia, Pascal |
| W. L. Gore & Associates, INC. | $43,885.29 | 2019-2025 | Gore Cardioform Septal Occluder, Gore Cardioform Asd Occluder, Product In Development |
| Boston Scientific Corporation | $27,832.91 | 2019-2025 | Watchman Flx, Synergy |
| Merit Medical Systems INC | $3,900.00 | 2024 | |
| Medtronic Vascular, INC. | $1,832.75 | 2019 | |
| Abbott Laboratories | $1,127.85 | 2024-2025 | Triclip, Mitraclip |
| Shockwave Medical, INC | $908.97 | 2024-2025 | Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Philips North America LLC | $787.01 | 2024 | (Bs3) Intracardiac Und, (Ao0) Igt Devices Intracardiac |
| Artivion, INC. | $718.50 | 2019 | |
| Medtronic, INC. | $351.24 | 2023 | Corevalve Evolut R |
| Abiomed | $148.34 | 2023-2025 | Impella |
| Biotronik INC. | $94.36 | 2019 | |
| Recor Medical INC | $38.11 | 2024 | Paradise Renal Denervation System |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anwar Tandar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.